MA28347A1 - Dérivés de quinoléine substitués - Google Patents

Dérivés de quinoléine substitués

Info

Publication number
MA28347A1
MA28347A1 MA29241A MA29241A MA28347A1 MA 28347 A1 MA28347 A1 MA 28347A1 MA 29241 A MA29241 A MA 29241A MA 29241 A MA29241 A MA 29241A MA 28347 A1 MA28347 A1 MA 28347A1
Authority
MA
Morocco
Prior art keywords
quinoline derivatives
substituted quinoline
substituted
derivatives
quinoline
Prior art date
Application number
MA29241A
Other languages
English (en)
Inventor
Peter Bertinato
Michel Andre Couturier
Ernest Seiichi Hamanaka
Marcus Douglas Ewing
Ralph Pelton Robinson Jr
Derek Lawrence Tickner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA28347A1 publication Critical patent/MA28347A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
MA29241A 2004-02-04 2006-08-04 Dérivés de quinoléine substitués MA28347A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54167804P 2004-02-04 2004-02-04
US63376304P 2004-12-06 2004-12-06

Publications (1)

Publication Number Publication Date
MA28347A1 true MA28347A1 (fr) 2006-12-01

Family

ID=34890449

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29241A MA28347A1 (fr) 2004-02-04 2006-08-04 Dérivés de quinoléine substitués

Country Status (25)

Country Link
US (3) US7468378B2 (fr)
EP (1) EP1716137A1 (fr)
JP (1) JP2007520543A (fr)
KR (1) KR100799802B1 (fr)
AP (1) AP2006003685A0 (fr)
AR (1) AR047529A1 (fr)
AU (1) AU2005214159A1 (fr)
BR (1) BRPI0507462A (fr)
CA (1) CA2555133A1 (fr)
CO (1) CO5700721A2 (fr)
CR (1) CR8544A (fr)
EA (1) EA010369B1 (fr)
EC (1) ECSP066717A (fr)
GE (1) GEP20084360B (fr)
IL (2) IL176715A0 (fr)
MA (1) MA28347A1 (fr)
NL (1) NL1028192C2 (fr)
NO (1) NO20063928L (fr)
OA (1) OA13365A (fr)
PA (1) PA8623001A1 (fr)
PE (1) PE20050773A1 (fr)
SV (1) SV2007002007A (fr)
TW (2) TWI306454B (fr)
UY (1) UY28734A1 (fr)
WO (1) WO2005080373A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
KR100799802B1 (ko) * 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20070203139A1 (en) * 2004-04-14 2007-08-30 Astrazeneca Ab Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
NZ563009A (en) 2005-04-19 2011-05-27 Surface Logix Inc Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion
ATE520651T1 (de) * 2006-10-23 2011-09-15 Pfizer Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
WO2008097471A1 (fr) * 2007-02-02 2008-08-14 Shivvers Steve D Dispositif de séchage à haut rendement équipé de zones de chauffage et de séchage à plusieurs étages
US20080249130A1 (en) * 2007-02-09 2008-10-09 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
WO2009014674A1 (fr) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Hétérocyclylamides comme inhibiteurs de la protéine de transport de triglycérides microsomal de l'intestin
ES2748136T3 (es) 2007-10-15 2020-03-13 United Animal Health Inc Método para aumentar el rendimiento de las crías
CA2702984C (fr) * 2007-10-19 2017-04-11 Sarcode Corporation Compositions et procedes pour le traitement de la retinopathie diabetique
WO2010018547A1 (fr) * 2008-08-13 2010-02-18 Pfizer Inc. Composés aminoquinoline
EP2723718A1 (fr) 2011-06-24 2014-04-30 Amgen Inc. Antagonistes de trpm8 et leur utilisation dans le cadre thérapeutique
AP2013007331A0 (en) 2011-06-24 2013-12-31 Amgen Inc TRPM8 antagonists and their use in treatments
ES2552989T3 (es) * 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
EP3107540A4 (fr) * 2014-02-17 2017-08-30 Hetero Research Foundation Polymorphes de lomitapide et ses sels
TW202140422A (zh) 2014-10-06 2021-11-01 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
US10138206B2 (en) 2014-10-09 2018-11-27 Glenmark Pharmaceuticals Limited Amorphous form of lomitapide mesylate
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
GEP20217329B (en) 2016-09-30 2021-12-10 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EA202192783A1 (ru) 2016-12-09 2022-02-24 Вертекс Фармасьютикалз Инкорпорейтед Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
JP6906105B2 (ja) * 2017-06-16 2021-07-21 成都先導薬物開発股▲ふん▼有限公司Ｈｉｔｇｅｎ Ｌｔｄ． Ｒｏｃｋを阻害する化合物及びその使用
IL272032B2 (en) 2017-07-17 2026-04-01 Vertex Pharma Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and
MA49752A (fr) 2017-08-02 2021-04-21 Vertex Pharma Procédés de préparation de composés de pyrrolidine
CA3078893A1 (fr) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Formes cristallines et compositions de modulateurs de cftr
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (fr) 2018-04-13 2019-10-17 Alexander Russell Abela Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2819039A1 (de) 1978-04-29 1979-11-08 Bayer Ag Leimungsmittel fuer papier
NZ199968A (en) 1981-03-11 1985-10-11 Wellcome Found Benzoic acid derivatives and naphthoic acid derivatives and pharmaceutical compositions
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
HU218419B (hu) 1992-03-06 2000-08-28 E.R. Squibb And Sons, Inc. Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
DE69531458T2 (de) 1994-05-27 2004-08-05 Glaxosmithkline S.P.A. Chinolinderivate als tachykinin nk3 rezeptor antagonisten
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19519245C2 (de) * 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US5919795A (en) 1995-06-07 1999-07-06 Pfizer Inc. Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion
WO1996040640A1 (fr) 1995-06-07 1996-12-19 Pfizer Inc. DERIVES DE BIPHENYL-2-ACIDE CARBOXYLIQUE-TETRAHYDRO-ISOQUINOLEINE-6-YL AMIDES, PREPARATION DE CES AMIDES ET UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE TRIGLYCERIDE MICROSOMAL ET/OU DE LA SECRETION D'APOLIPOPROTEINES B (Apo B)
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
NZ332341A (en) * 1996-05-20 2000-05-26 Darwin Discovery Ltd Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors
CA2259431A1 (fr) 1996-07-01 1998-01-08 Eli Lilly And Company Composes hypoglycemiques et hypolipidemiques
KR100217618B1 (ko) * 1996-12-12 1999-09-01 정몽규 와셔액 분사위치 조절 장치
WO1998027979A1 (fr) 1996-12-20 1998-07-02 Bristol-Myers Squibb Company Inhibiteurs heterocycliques de la proteine de transfert des triglycerides microsomiques et methode associee
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US5968950A (en) 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
AP1201A (en) 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
EP1042295B1 (fr) * 1997-12-22 2005-09-07 Pharmacia & Upjohn Company LLC 4-hydroxyquinoline-3-carboxamides et hydrazides utilises comme agents antiviraux
CO5090829A1 (es) 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
CA2325358C (fr) * 1999-11-10 2005-08-02 Pfizer Products Inc. Amides de l'acide 7-¬(4'-trifluoromethylbiphenyl-2-carbonyl)amino|-quinoleine-3-carboxylique et methodes pour inhiber la secretion d'apolipoproteine b
IL139449A0 (en) 1999-11-10 2001-11-25 Pfizer Prod Inc Use of apo b secretion/mtp inhibitors
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
US6417367B1 (en) * 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
NZ525591A (en) 2000-10-05 2004-04-30 Fujisawa Pharmaceutical Co Benzamide compounds as Apo B secretion inhibitors
BR0210616A (pt) 2001-06-28 2004-09-28 Pfizer Prod Inc Indóis, benzofuranos e benzotiofenos substituìdos com triamida, composição farmacêutica, uso dos referidos compostos, bem como processo para preparação dos mesmos
CZ2004634A3 (cs) * 2001-10-25 2004-10-13 Takedaáchemicaláindustriesźáltd Chinolinová sloučeninaŹ způsob výroby a použití a farmaceutický přípravek
AU2002360489A1 (en) * 2001-12-07 2003-06-23 The Regents Of The University Of California Treatment for age-related macular degeneration
US20030162788A1 (en) * 2002-01-10 2003-08-28 Boehringer Ingelheim Pharma Kg Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
ZA200502496B (en) 2002-02-28 2005-10-12 Japan Tobacco Inc Ester compound and medicinal use thereof.
EP1581499A1 (fr) * 2002-12-20 2005-10-05 Pfizer Products Inc. Inhibiteurs de proteine de transfert de triglyceride microsomale
WO2004056777A1 (fr) * 2002-12-20 2004-07-08 Pfizer Products Inc. Inhibiteurs de proteine microsomale de transfert de triglyceride
KR100799802B1 (ko) * 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물

Also Published As

Publication number Publication date
NO20063928L (no) 2006-10-31
AP2006003685A0 (en) 2006-08-31
OA13365A (en) 2007-04-13
AR047529A1 (es) 2006-01-25
BRPI0507462A (pt) 2007-07-10
NL1028192A1 (nl) 2005-08-08
NL1028192C2 (nl) 2006-05-30
CA2555133A1 (fr) 2005-09-01
KR20060127123A (ko) 2006-12-11
UY28734A1 (es) 2005-09-30
US20060223851A1 (en) 2006-10-05
US20050234099A1 (en) 2005-10-20
CO5700721A2 (es) 2006-11-30
EA010369B1 (ru) 2008-08-29
SV2007002007A (es) 2007-03-20
US20070093525A1 (en) 2007-04-26
IL208963A0 (en) 2011-07-31
CR8544A (es) 2006-11-30
WO2005080373A1 (fr) 2005-09-01
IL176715A0 (en) 2006-10-31
EA200601239A1 (ru) 2007-02-27
EP1716137A1 (fr) 2006-11-02
KR100799802B1 (ko) 2008-01-31
TW200906800A (en) 2009-02-16
GEP20084360B (en) 2008-04-29
JP2007520543A (ja) 2007-07-26
AU2005214159A1 (en) 2005-09-01
PE20050773A1 (es) 2005-10-26
TWI306454B (en) 2009-02-21
TW200533354A (en) 2005-10-16
PA8623001A1 (es) 2006-03-24
US7468378B2 (en) 2008-12-23
US7393958B2 (en) 2008-07-01
ECSP066717A (es) 2006-10-31
US7368573B2 (en) 2008-05-06

Similar Documents

Publication Publication Date Title
CY2022001I2 (el) Παραγωγα του uk-2a
IS8578A (is) 3- karbamoýl - 2- pýridón afleiður
MA28396B1 (fr) Dérivés de quinoléine nouveaux
EP2016080A4 (fr) Dérivés de dihydropyrazolopyrimidinones
ATE394399T1 (de) Tetrahydropyridoindolderivate
ATE540935T1 (de) Chinazolinderivate
NL1028192A1 (nl) Gesubstitueerde chinolineverbindingen.
IS2581B (is) Kínólín afleiður sem fosfódíesterasa hindrar
ATE553079T1 (de) Heteroarylphenylharnstoffderivat
ATE383361T1 (de) Pyrrazolopyrimidinderivate
ATE434613T1 (de) Isochinolinderivate
MA28554B1 (fr) Dérivés de morpholine
ATE417830T1 (de) Sulfonylbenzimidazolderivate
MA28686B1 (fr) Derives de pyrrolopyridine
DE602006010581D1 (de) 4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
EP2043633A4 (fr) Dérivés de thiadiazolidinone
ATE404546T1 (de) Substituierte n-sulfonylaminobenzyl-2- phenoxyacetamidverbindungen
ATE485294T1 (de) Azaindol-2-carboxamid-derivate
ATE430142T1 (de) Phenylpiperazin-methanon-derivate
ATE527255T1 (de) Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da) Tiglien-3-onderivater
ATE404542T1 (de) 4-phenylpyrimidin-2-carbonitrilderivate
ATE365731T1 (de) 4-amino-5-cyanopyrimidinderivate
EP1867636A4 (fr) Dérivé de pyridylméthylsulfone
DE602006014973D1 (de) Neuartige cercosporamidderivate